*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1991 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus and should not be redistributed.  Any       *x*
*x*    research using this corpus or based on it should acknowledge     *x*
*x*    that fact, as well as the preliminary nature of the corpus.      *x*
*x*                             (9/9/1991)                             *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*


(  END_OF_TEXT_UNIT)
((NP Introduction))
((S
  (NP Muscle weakness)
  (AUX is)
  (ADVP now)
  (VP recognized
      (PP as
	  (NP an
	      (ADJP (ADJP uncommon)
		    (X though
		       (ADJP serious)))
	      complication
	      (PP of
		  (NP steroid therapy))
	      ,
	      (PP with
		  (NP most
		      (PP of
			  (NP the
			      synthetic adrenal
			      corticosteroids
			      (PP in
				  (NP clinical use))))))))))  
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (SBAR Although
	 (S (NP biopsies)
	    (AUX have)
	    (VP shown
		(NP structural changes)
		(PP in
		    (NP some
			(PP of
			    (NP the (VP reported) cases
				(PP of
				    (NP (ADJP steroid-induced) weakness)))))))))
   ,
   (S (NP this case)
      (VP provides
	  (NP (NP (NP the only example)
		  (VP known
		      (PP to
			  (NP us))))
	      (SBAR  
	       (WHPP in
		     (WHNP which))
	       (S (NP necropsy)
		  (VP afforded
		      (NP the opportunity
			  (PP for
			      (NP extensive study
				  (PP of
				      (NP multiple muscle groups))))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP (NP The case)
       (VP described
	   (PP in
	       (NP this paper))))
   (VP is
       (NP that
	   (PP of
	       (NP (NP an
		       older
		       man)
		   (SBAR  
		    (WHNP who)
		    (S (NP T)
		       (VP developed
			   (NP  (VP disabling)
				muscular weakness))
		       (SBAR while
			     (S  (NP *)  
				 (VP receiving
				     (NP a variety
					 (PP of
					     (NP steroids)))
				     (PP for
					 (NP a refractory anemia))))))))))))
  .) 
(  END_OF_TEXT_UNIT)
( (NP Report
      (PP of
	  (NP case)))
  )
( (S
   (NP This patient)
   (VP was
       (NP (NP a
	       (ADJP 65-year-old) white male
	       accountant)
	   (SBAR 
	    (WHNP who)
	    (S (NP T)
	       (VP entered
		   (NP the New York Hospital)
		   (PP for
		       (NP his (ADJP fourth and terminal) admission))
		   (PP on
		       (NP (NP June 26) ,
			   (NP 1959))))
	       ,
	       (ADVP because
		     (PP of
			 (NP (NP (VP disabling)
				 weakness)
			     and
			     (NP general debility)))))))))
  .) 
(  END_OF_TEXT_UNIT)
( (S (PP In
	 (NP 1953))
     (S
      (NP the patient)
      (VP developed
	  (NP (NP an (ADJP unexplained) anemia)
	      (SBAR (WHPP for
			  (WHNP which))
		    (S
		     (NP 15 blood transfusions)
		     (AUX were)
		     (VP given)
		     (PP over
			 (NP a period
			     (PP of
				 (NP 4 years))))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Splenomegaly)
      (AUX was)
      (ADVP first)
      (VP noted)
      (PP in
	  (NP 1956)))
     ,
     and
     (S (NP a sternal marrow biopsy
	    (PP at
		(NP that time)))
	(VP showed
	    (NP ``
		(NP (ADJP scattered)
		    foci
		    (PP of
			(NP fibrosis)))
		''
		(ADJP suggestive
		      (PP of
			  (NP myelofibrosis)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP No additional transfusions)
   (VP were
       (ADJP necessary))
   (PP after
       (NP the institution
	   (PP of
	       (NP prednisone))
	   (PP in
	       (NP (NP July)
		   ,
		   (NP 1957)))
	   ,
	   (PP in
	       (NP an initial dose
		   (PP of
		       (NP 40 mg.
			   (ADVP daily)))
		   (PP with
		       (NP  
			gradual
			tapering
			(PP to
			    (NP 10 mg.
				(ADVP daily))))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP This medication)
   (AUX was)
   (VP continued
	     
       (PP until
	   (NP (NP February)
	       ,
	       (NP 1958)))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP (NP February)
	   ,
	   (NP 1958)))
   ,
   (S (NP the patient)
      (VP suffered
	  (NP (NP a myocardial infarction)
	      (VP complicated
		  (PP by
		      (NP pulmonary edema)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Additional findings
       (PP at
	   (NP this time)))
   (VP included
       (NP (NP cardiomegaly)
	   ,
	   (NP peripheral arteriosclerosis obliterans)
	   ,
	   and
	   (NP cholelithiasis))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The hemoglobin)
   (VP was
       (NP 11.6 gm .)))
  .)
( (S
   (NP Therapy)
   (VP included
       (NP (NP digitalization) and (NP anticoagulation))))
  .)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Later)
      ,
      (S (NP chlorothiazide and salt restriction)
	 (VP became
	     (ADJP necessary))
	 (S (NP *)
	    (AUX to)
	    (VP control
		(NP the edema
		    (PP of
			(NP 
			 chronic congestive
			 failure)))))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (ADVP  Because
	  (PP of
	      (NP (VP increasing)
		  anemia)))
   ,
   (S  
    (NP (NP triamcinolone)
	,
	(NP 8 mg.
	    (ADVP daily))
	,)
    (X (X (AUX was)
	  (VP started
	    
	      (PP on
		  (NP (NP Feb. 23) ,
		      (NP 1958)))))
       ,
       and
       (X  
	(AUX was)
	(VP continued
	    
	    (PP until
		(NP (NP July)
		    ,
		    (NP 1958))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S  
      (PP In
	  (NP (NP September)
	      ,
	      (NP 1958)))
      ,
      (S (NP the patient)
	 (VP developed
	     (NP (NP generalized weakness and fatigue)
		 (SBAR  
		  (WHNP which)
		  (S (NP T)
		     (VP was
			 (ADJP concurrent
			       (PP with
				   (NP exacerbation
				       (PP of
					   (NP his anemia))))))))))))
     ;
     ;
     (S (NP the hemoglobin)
	(VP was
	    (NP 10.6 gm
		.))))
  .)
( (S  (PP In
	  (NP an attempt
	      (S (NP *)
		 (AUX to)
		 (VP reverse
		     (NP the downhill trend)
		     (PP by
			 (S (NP *) 
			    (VP (VP stimulating
				    (NP the bone marrow))
				and
				(VP controlling
				    (NP any hemolytic component)))))))))
      ,
      (S  
       (NP (NP triamcinolone)
	   ,
	   (NP 16 mg.
	       (ADVP daily))
	   ,)
       (AUX was)
       (VP (VP begun
	  
	       (PP on
		   (NP (NP Sept. 26)
		       ,
		       (NP 1958))))
	   ,
	   and
	   (VP continued
	       (PP until
		   (NP (NP Feb. 18)
		       ,
		       (NP 1959)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S  
      (PP At
	  (ADVP first))
      (S (S
	  (NP the patient)
	  (VP felt
	      (ADJP stronger)))
	 ,
	 and
	 (S (NP the hemoglobin)
	    (VP rose
		(PP to
		    (NP 13.8 gm.))))))
     ,
     but
     (S (PP on
	    (NP (NP Oct. 20)
		,
		(NP 1958)))
	,
	(S (NP he)
	   (VP complained
	       (PP of
		   (S  (NP *)   
		       (VP ``
			   caving
			   (PRT in)
			   ''
			   (PP in
			       (NP his knees)))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP By
       (NP (NP Nov. 8) , (NP 1958)))
   ,
   (S (S  
       (NP (NP weakness)
	   ,
	   (VP  (ADVP specifically)
		involving
		(NP the pelvic and thigh musculature))
	   ,)
       (VP was
	   (ADJP pronounced)))
      ,
      and
      (S (NP a common complaint)
	 (VP was
	     ``
	     (NP difficulty
		 (PP in
		     (S (NP *) 
			(VP stepping
			    (ADVP up)
			    (PP on
				(PP to
				    (NP curbs)))))))
	     ''))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (NP Prednisone)
      ,
      (NP 30 mg.
	  (ADVP daily))
      ,)
  (AUX was)
  (VP substituted
	 
      (PP for
	  (NP triamcinolone)))
  (PP (PP from
	  (NP Nov. 22))
      (PP until
	  (NP (NP Dec. 1)
	      ,
	      (NP 1958))))
  ,
  (PP without
      (NP any improvement
	  (PP in
	      (NP the weakness)))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Serum potassium)
      (PP at
	  (NP this time))
      (VP was
	  (NP 3.8 mEq.
	      (PP per
		  (NP liter)))))
     ,
     and
     (S (NP the hemoglobin)
	(VP was
	    (NP 13.9 gm))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S  
      (PP By
	  (NP (NP Dec. 1) 
	      ,
	      (NP 1958)))
      ,
      (S (NP the weakness
	     (PP in
		 (NP the pelvic and quadriceps muscle groups)))
	 (VP was
	     (ADJP (ADVP appreciably)
		   worse))))
     ,
     and
     (S (NP it
	    (PP-1 *pseudo-attach*))
	(VP became
	    (ADJP difficult))
	(PP-1 for
	      (S (NP the patient)
		 (AUX to)
		 (VP rise
		     (ADJP unaided)
		     (PP from
			 (NP a (ADJP sitting
				     or
				     reclining)
			     position)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (NP Triamcinolone)
      ,
      (NP 16 mg.
	  (ADVP daily))
      ,)
  (AUX was)
  (VP (VP resumed)
      and
      (VP maintained
	  (PP until
	      (NP (NP Feb. 18)
		  ,
		  (NP 1959))))))
 .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Chlorothiazide)
      (AUX was)
      (VP omitted
	     
	  (PP for
	      (NP a (ADJP 2-week) period))))
     ,
     but
     (S (NP there)
	(VP was
	    (NP no change
		(PP in
		    (NP the muscle weakness))))))
  .)
(  END_OF_TEXT_UNIT)
( (S (PP At
	 (NP this time))
     (S
      (NP a
	  (ADJP detailed) neuromuscular
	  examination)
      (VP revealed
	  (NP (NP diffuse muscle atrophy)
	      (SBAR (WHNP that)
		    (S  (NP T) 
			(VP was
			    (ADJP (ADJP moderate
					(PP in
					    (NP the hands and feet)))
				  ,
				  but
				  (ADJP  marked
					 (PP in
					     (NP the shoulders
						 ,
						 hips
						 ,
						 and
						 pelvic girdle))))
			    ,
			    (PP with
				(NP hypoactive deep-tendon reflexes)))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP No fasciculations
      or
      sensory defects)
  (AUX were)
  (VP found))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Electromyography)
   (VP revealed
       (NP no evidence
	   (PP of
	       (NP 
		lower
		motor neuron disease)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Thyroid function tests)
   (VP yielded
       (NP normal results)))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The (ADJP protein-bound) iodine)
      (VP was
	  (NP 6.6 mg.)))
     ,
     and
     (S (NP the radioactive iodine uptake
	    (PP over
		(NP the thyroid gland)))
	(VP was
	    (NP 46 %
		(PP in
		    (NP 24 hours)))
	    ,
	    (PP with
		(NP a conversion ratio
		    (PP of
			(NP 12 %)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP A Schilling test)
   (VP demonstrated
       (NP normal absorption
	   (PP of
	       (NP vitamin A[fj])))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP (NP February)
	   ,
	   (NP 1959)
	   ,))
   (PP during
       (NP the second admission
	   (PP to
	       (NP The New York Hospital))))
   ,
   (S (NP a biopsy specimen
	  (PP of
	      (NP the left gastrocnemius)))
      (VP showed
	  (NP (NP (ADJP striking)
		  increase
		  (PP in
		      (NP the sarcolemmal sheath nuclei)))
	      and
	      (NP shrunken
		  muscle fibers
		  (PP in
		      (NP several sections)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Serial serum potassium levels)
      (VP remained
	  (ADJP normal)))
     ;
     ;
     (S (NP the serum glutamic oxaloacetic transaminase)
	(VP was
	    (NP 10 units
		(PP per
		    (NP ml.))
		(PP per
		    (NP min .))))))
  .)
( (S
   (NP The clinical impression
       (PP at
	   (NP this time)))
   (VP was
       (NP  either
	    (NP muscular dystrophy) or (NP polymyositis))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP On
       (NP (NP Feb. 12)
	   ,
	   (NP 1959)))
   ,
   (S  
    (NP (NP  (ADJP purified)
	     corticotropin)
	*LRB*
	(NP ACTH Gel)
	*RRB*
	,
	(NP 20 units
	    (ADVP daily)
	    (ADVP intramuscularly))
	,)
    (X (X (AUX was)
	  (VP started))
       but
       (VP had
	   (S (NP *)
	      (AUX to)
	      (VP be
		  (VP discontinued))
	      (ADVP (NP 3 weeks)
		    later)
	      (ADVP because
		    (PP of
			(NP excessive fluid retention))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP (PP From
	   (NP March 3))
       (PP to
	   (NP (NP May 1)
	       ,
	       (NP 1949))))
   ,
   (S (NP the patient)
      (AUX was)
      (VP maintained
	      
	  (PP on
	      (NP (NP dexamethasone)
		  ,
		  (NP (NP 3
			  (PP to
			      (NP 6)))
		      mg.
		      (ADVP daily)))))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP May 1959))
   ,
   (S  
    (NP (NP prednisone)
	,
	(NP 30 mg.
	    (ADVP daily))
	,)
    (VP replaced
	(NP the dexamethasone))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Muscle weakness)
      (AUX did)
      (NEG not)
      (VP improve))
     ,
     and
     (S (NP the patient)
	(VP needed
	    (NP (NP (ADVP first)
		    a cane)
		,
		(NP (ADVP then)
		    crutches)))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP spite
	   (PP of
	       (NP normal thyroid function tests))))
   ,
   (S  (NP (NP a trial
	       (PP of
		   (NP propylthiouracil)))
	   ,
	   (NP 400 mg.
	       (ADVP daily)
	       (PP for
		   (NP one week)))
	   ,)
       (X (X (AUX was)
	     (VP given))
	  but
	  (VP served
	      (ADVP only)
	      (S (NP *)
		 (AUX to)
		 (VP intensify
		     (NP muscle weakness)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (VP Repeated)
      attempts
      (S (NP *)
	 (AUX to)
	 (VP withdraw
	     (NP steroids)
	     (ADVP entirely))))
  (VP were
      (ADJP unsuccessful))
  (SBAR because
	(S (NP (NP (VP increased)
		   muscle weakness)
	       (ADVP-2 *pseudo-attach*))
	   (VP resulted)
	   ,
	   (ADVP-2 as
		   well
		   (PP as
		       (NP (NP fever)
			   ,
			   (NP malaise)
			   ,
			   (NP anorexia)
			   ,
			   (NP anxiety)
			   ,
			   and
			   (NP an exacerbation
			       (PP of
				   (NP the anemia)))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP These reactions)
   (AUX were)
   (VP interpreted
	     
       (PP as
	   (S (NP *) 
	      (VP being
		  (NP manifestations
		      (PP of
			  (NP hypoadrenocorticism))))))))
  .)
(  END_OF_TEXT_UNIT)
((S  
  (NP Severe back pain)
  (PP in
      (NP (NP June)
	  ,
	  (NP 1959)
	  ,))
  (VP prompted
      (NP a third hospital admission)))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Extensive osteoporosis
       (PP with
	   (NP partial collapse
	       (PP of
		   (NP D8)))))
   (AUX was)
   (VP found))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP (NP A (ADJP high-protein) diet)
      ,
      (NP calcium lactate supplements)
      ,
      and
      (NP norethandrolone))
  (VP failed
      (S (NP *)
	 (AUX to)
	 (VP change
	     (NP (NP the skeletal complaint)
		 or
		 (NP the severe muscle weakness))))))
 .)
(  END_OF_TEXT_UNIT)
( 
 (S  
  (NP The terminal hospital admission
      (PP on
	  (NP (NP June 27)
	      ,
	      (NP 1959)
	      ,)))
  (AUX was)
  (VP necessitated
       
      (PP by
	  (NP (NP (VP continued)
		  weakness and debility)
	      (VP complicated
		  (PP by
		      (NP (NP urinary retention)
			  and
			  (NP painful
			      thrombosed
			      hemorrhoids))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP X-ray films
       (PP of
	   (NP the vertebral column)))
   (VP showed
       (NP progression
	   (PP of
	       (NP the demineralization)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP On
       (NP (NP July 4)
	   ,
	   (NP 1959)
	   ,))
   (S (NP the patient)
      (VP (VP developed
	      (NP  (ADJP marked)
		   abdominal pain and distension))
	  ,
	  (VP went
	      (PP into
		  (NP shock)))
	  ,
	  and
	  (VP died))))
  .)
(  END_OF_TEXT_UNIT)
( (NP Findings
      (PP at
	  (NP necropsy))))
( (S
   (NP The body)
   (VP was
       (NP that
	   (PP of
	       (NP (NP a
		       (ADJP (ADJP well-developed)
			     ,
			     (ADJP (ADVP somewhat)
				   debilitated))
		       white man)
		   (VP weighing
		       (NP 108 lb
			   .)))))))
  .)
( (S (S
      (NP There)
      (VP were
	  (NP (NP bilateral pterygia) and (NP arcus senilis))))
     ,
     and
     (S (NP the mouth)
	(VP was
	    (ADJP edentulous))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The heart)
      (VP weighed
	  (NP 510 gm.)))
     ,
     and
     (S (PP at
	    (NP the outflow tracts))
	(S (NP the (ADJP left and right) ventricles)
	   (VP measured
	       (NP (NP (NP (NP 19)
			   and
			   (NP 3))
		       mm.)
		   ,
		   (ADVP respectively))))))
  .) 
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The coronary arteries)
      (VP were
	  (ADJP sclerotic
		and
		diffusely
		narrowed
		(PP throughout
		    (NP their courses)))))
     ,
     and
     (S (NP the
	    right
	    coronary artery)
	(AUX was)
	(VP  (ADVP virtually)
	     occluded
	     
	     (PP by
		 (NP (NP a
			 yellow atheromatous
			 plaque)
		     (ADJP (NP 1.5
			       cm.)
			   distal
			   (PP to
			       (NP its origin))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The myocardium
       (PP of
	   (NP the posterior base
	       (PP of
		   (NP the left ventricle)))))
   (AUX was)
   (VP replaced
	     
       (PP by
	   (NP gray scar tissue
	       (PP over
		   (NP a 7.5 cm. area))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The valves)
   (VP were
       (ADJP normal))
   (PP except
       (PP for
	   (NP thin yellow
	       plaques
	       (PP on
		   (NP the inferior surface
		       (PP of
			   (NP the mitral leaflets))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Microscopically)
      ,
      (S (NP sections
	     (PP from
		 (NP the posterior base
		     (PP of
			 (NP the left ventricle
			     (PP of
				 (NP the heart)))))))
	 (VP showed
	     (NP several large areas
		 (PP of
		     (NP replacement
			 (PP of
			     (NP muscle))
			 (PP by
			     (NP fibrous tissue))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP addition))
   ,
   (S (NP other sections)
      (VP contained
	  (NP (NP focal areas
		  (PP of
		      (NP 
		       recent myocardial
		       necrosis)))
	      (SBAR (WHNP that)
		    (S  (NP T) 
			(AUX were)
			(VP infiltrated
			    (PP with
				(NP neutrophils)))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP  Many
       (PP of
	   (NP the myocardial fibers)))
  (X (X (AUX were)
	(VP hypertrophied))
     and
     (VP had
	 (NP 
	  large
	  ,
	  irregular
	  ,
	  basophilic
	  nuclei))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The intima
       (PP of
	   (NP the
	       larger coronary
	       arteries)))
   (AUX was)
   (VP thickened
	     
       (PP by
	   (NP (NP fibrous tissue)
	       (VP containing
		   (NP (NP fusiform clefts)
		       and
		       (NP mononuclear cells)))))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The intimal surface
	  (PP of
	      (NP the aorta)))
      (AUX was)
      (VP covered
	     
	  (PP with
	      (NP 
	       confluent
	       ,
	       (ADJP yellow-brown)
	       ,
	       hard
	       ,
	       friable
	       plaques
	       (PP along
		   (NP its entire course))))))
     ,
     and
     (S (NP there)
	(VP was
	    (NP a (ADJP marked) narrowing
		(PP of
		    (NP the orifices
			(PP of
			    (NP the
				large major visceral
				arteries))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (ADJP particular))
   ,
   (S (S (NP the orifices
	     (PP of
		 (NP the
		     right
		     (ADJP renal and celiac) arteries)))
	 (VP  were
	      (ADJP   (ADVP virtually)
		      occluded
		      )))
      ,
      and
      (S (NP  both
	      calcified
	      common iliac
	      arteries)
	 (VP were
	     (ADJP   (ADVP completely)
		     occluded
		     )))))
  .)
(  END_OF_TEXT_UNIT)
(  
 (S (NP The lungs)
    (VP weighed
	(ADVP together)
	(NP 950 gm
	    .)))
 .)
(  (S (PP On
	  (NP the surfaces
	      (PP of
		  (NP both
		      lungs))))
      (S (NP there)
	 (VP were
	     (NP (NP emphysematous blebs)
		 (VP measuring
		     (NP (PP up
			     (PP to
				 (NP 3)))
			 cm.
			 (PP in
			     (NP diameter))))))))
   .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The parenchyma)
      (VP was
	  (ADJP slightly
		hyperemic)
	  (PP in
	      (NP the apex
		  (PP of
		      (NP the left lung))))))
     ,
     and
     (S (NP there)
	(VP were
	    (NP (NP several firm
		    ,
		    gray
		    ,
		    fibrocalcific nodules)
		(VP measuring
		    (ADJP  as
			   large
			   (PP as
			       (NP 3 mm
				   .))))))))
  .)
( (S  (ADVP Microscopically)
      ,
      (S (NP there)
	 (VP was
	     (NP (NP emphysema)
		 ,
		 (NP fibrosis)
		 ,
		 and
		 (NP vascular congestion)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP (NP Macrophages)
	  (VP laden
	      (PP with
		  (NP brown pigment))))
      (AUX were)
      (VP seen
	     
	  (PP in
	      (NP some
		  (PP of
		      (NP the alveoli))))))
     ,
     and
     (S (NP the intima
	    (PP of
		(NP some
		    (PP of
			(NP the small arteries)))))
	(AUX was)
	(VP thickened
	     
	    (PP by
		(NP fibrous tissue)))))
  .)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The
	  firm red
	  spleen)
      (VP weighed
	  (NP 410 gm.)))
     ,
     and
     (S (NP its surface)
	(AUX was)
	(VP mottled
	     
	    (PP by
		(NP 
		 discrete
		 ,
		 small
		 patches
		 (PP of
		     (NP white material)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S (S (NP (NP The endothelial cells)
	   (VP lining
	       (NP the sinusoids)))
       (VP were
	   (ADJP prominent)))
    ,
    and
    (S (NP many)
       (VP contained
	   (NP large quantities
	       (PP of
		   (NP hemosiderin))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Some
	  (PP of
	      (NP the sinusoids)))
      (VP contained
	  (NP large numbers
	      (PP of
		  (NP (VP nucleated)
		      red cells)))))
     ,
     and
     (S (NP cells
	    (PP of
		(NP the granulocytic series)))
	(AUX were)
	(VP found
	     
	    (PP in
		(NP small numbers)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP There)
   (VP were
       (NP (NP slight fibrosis)
	   and
	   (NP  (ADJP marked)
		arteriolosclerosis))))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (S (NP The liver)
      (VP (VP weighed
	      (NP 2,090 gm.))
	  ,
	  (VP was
	      (ADJP brown
		    (PP in
			(NP color))))))
   ,
   and
   (S (NP the cut surface)
      (AUX was)
      (VP mottled
	     
	  (PP by
	      (NP 
	       irregular pale
	       areas)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Microscopically)
      ,
      (S (S (NP there)
	    (VP was
		(NP hyperemia
		    (PP of
			(NP the central veins)))))
	 ,
	 and
	 (S (NP there)
	    (VP was
		(NP some atrophy
		    (PP of
			(NP adjacent parenchyma)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Some liver cord cells)
   (VP contained
       (NP (VP vacuolated)
	   cytoplasm))
   ,
   (SBAR while
	 (S (NP others)
	    (VP had
		(NP small amounts
		    (PP of
			(NP brown hemosiderin pigment)))))))
  .)
(  END_OF_TEXT_UNIT)
( (S
   (NP The gallbladder)
   (VP contained
       (NP (NP (ADVP about)
	       40 cc.
	       (PP of
		   (NP (ADJP green-brown) bile)))
	   and
	   (NP (NP 3
		   smooth
		   ,
		   (ADJP dark-green) calculi)
	       (VP measuring
		   (NP (PP up
			   (PP to
			       (NP 1)))
		       cm.
		       (PP in
			   (NP diameter))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S
   (NP The mucosa
       (PP of
	   (NP the stomach)))
   (VP was
       (ADJP (ADJP atrophic)
	     and
	     (ADJP   irregularly
		     blackened))
       (PP over
	   (NP a 14 cm. area))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The (ADJP small and large) intestines)
      (AUX were)
      (VP filled
	     
	  (PP with
	      (NP gas))))
     ,
     and
     (S (NP the jejunum)
	(AUX was)
	(VP dilated
	     
	    (PP to
		(NP (NP (ADVP about)
			2 times)
		    its normal circumference)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The small intestine and colon)
      (VP contained
	  (NP  (ADVP approximately)
	       300 cc.
	       (PP of
		   (NP 
		    (ADJP foul-smelling)
		    ,
		    sanguineous
		    material)))))
     ,
     and
     (S (NP the mucosa
	    (ADVP throughout))
	(VP was
	    (ADJP (ADJP hyperemic) and (ADJP mottled green-brown)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP A careful search)
   (VP failed
       (S (NP *)
	  (AUX to)
	  (VP show
	      (NP occlusion
		  (PP of
		      (NP any
			  (PP of
			      (NP the mesenteric vessels)))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Microscopically)
      ,
      (S (NP the mucosa
	     (PP of
		 (NP the stomach)))
	 (VP (VP showed
		 (NP extensive cytolysis))
	     and
	     (VP contained
		 (NP large numbers
		     (PP of
			 (NP (ADJP Gram-negative)
			     bacterial
			     rods)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The submucosa)
   (AUX was)
   (VP  (ADVP focally)
	infiltrated
	     
	(PP with
	    (NP neutrophils))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP The mucosa
	  (PP of
	      (NP the jejunum and ileum)))
      (VP showed
	  (NP similar changes)))
     ,
     and
     (S  
      (PP in
	  (NP some areas))
      (S
       (NP the submucosa)
       (VP (VP was
	       (ADJP edematous))
	   and
	   (VP contained
	       (NP considerable numbers
		   (PP of
		       (NP neutrophils))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S
      (NP Some
	  (PP of
	      (NP the small vessels)))
      (AUX were)
      (VP filled
	     
	  (PP with
	      (NP fibrin thrombi))))
     ,
     and
     (S (NP there)
	(VP was
	    (NP  extensive interstitial
		 hemorrhage))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP A section
       (PP of
	   (NP the colon)))
   (VP revealed
       (NP (NP intense hyperemia)
	   and
	   (NP (NP 
		extensive focal
		ulcerations
		(PP of
		    (NP the mucosa)))
	       ,
	       (VP associated
		   (PP with
		       (NP (NP much fibrin)
			   and
			   (NP many neutrophils))))))))
  .)
(  END_OF_TEXT_UNIT)
( (S
   (NP (NP Cultures)
       (VP taken
	   (PP from
	       (NP the jejunum))))
   (VP yielded
       (NP (NP Monilia albicans)
	   ,
	   (NP Pseudomonas
	       pyocanea)
	   ,
	   (NP Aerobacter aerogenes)
	   ,
	   and
	   (NP Streptococcus anhemolyticus))))
  .)
(  END_OF_TEXT_UNIT)
( (S
   (NP The kidneys)
   (VP (VP were
	   (ADJP pale))
       and
       (VP weighed
	   (NP (NP (ADJP right)
		   ,
		   (NP 110 gm.)
		   ,)
	       and
	       (NP (ADJP left)
		   ,
		   (NP 230 gm
		       .))))))
  .)
( (S
   (NP The surfaces)
   (VP (VP were
	   (ADJP  (ADVP coarsely
			and
			finely)
		  granular))
       and
       (VP punctuated
	   (PP by
	       (NP (NP 
		    clear
		    ,
		    (ADJP fluid-filled)
		    cysts)
		   (VP measuring
		       (NP  
			(ADVP up
			      to)
			3 cm.
			(PP in
			    (NP diameter)))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (PP On
	 (NP the surface
	     (PP of
		 (NP the right kidney))))
     (S (NP there)
	(VP were
	    (ADVP also)
	    (NP (NP 2 yellow
		    ,
		    firm
		    ,
		    friable
		    (ADJP raised)
		    areas)
		(VP measuring
		    (NP (PP up
			    (PP to
				(NP 2)))
			cm.
			(PP in
			    (NP diameter))))))))
  .) 
(  END_OF_TEXT_UNIT)
( (S  (ADVP Microscopically)
      ,
      (S
       (NP  both
	    kidneys)
       (VP showed
	   (NP (NP many small cortical scars)
	       (SBAR 
		(WHPP in
		      (WHNP which))
		(S (NP there)
		   (VP was
		       (NP (NP (ADJP glomerular and interstitial) fibrosis)
			   ,
			   (NP tubular atrophy)
			   ,
			   and
			   (NP an infiltration
			       (PP of
				   (NP (NP lymphocytes) and (NP plasma cells))))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (NP Occasional tubules)
    (VP contained
	(NP (NP hyaline casts)
	    (VP admixed
		(PP with
		    (NP neutrophils))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Throughout)
      ,
      (S (NP there)
	 (AUX were)
	 (NP (NP (ADJP marked)
		 arteriolosclerosis) 
	     and 
	     (NP hyalinization
		 (PP of
		     (NP 
		      afferent glomerular
		      arterioles))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (NP These changes)
    (VP were
	(ADJP   more
		marked
		(PP in
		    (NP the
			atrophic right
			kidney))
		(PP than
		    (PP in
			(NP the left))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP addition))
   ,
   (S (NP there)
      (VP were
	  (NP 2 small papillary adenomas
	      (PP in
		  (NP the right kidney))))))
  .)
(  END_OF_TEXT_UNIT)
((S  
  (NP The bone
      (PP of
	  (NP the vertebral bodies
	      ,
	      ribs
	      ,
	      and
	      sternum)))
  (X (VP was
	 (ADJP soft))
     and
     (X  
      (AUX was)
      (VP  (ADVP easily)
	   compressed))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP The marrow
       (PP of
	   (NP the vertebral bodies)))
   (VP (VP was
	   (ADJP pale))
       and
       (VP showed
	   (NP areas
	       (PP of
		   (NP fatty replacement))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  (ADVP Microscopically)
      ,
      (S (NP there)
	 (VP were
	     (NP (NP many areas
		     (PP of
			 (NP hypercellularity)))
		 (VP alternating
		     (PP with
			 (NP areas
			     (PP of
				 (NP hypocellularity)))))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP The cells
      (PP of
	  (NP the (ADJP erythroid
			,
			myeloid
			,
			and
			megakaryocytic) series)))
  (VP were
      (ADJP normal)
      (PP except
	  (PP for
	      (NP their numbers)))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP There)
   (VP was
       (NP no evidence
	   (PP of
	       (NP fibrosis)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
((S  
  (NP The muscles
      (PP of
	  (NP the extremities
	      ,
	      chest wall
	      ,
	      neck
	      ,
	      and
	      abdominal wall)))
  (VP were
      (ADJP soft
	    ,
	    pale
	    ,
	    and
	    atrophic)))
 .)
(  END_OF_TEXT_UNIT)
((S  
  (NP Microscopic studies
      (PP of
	  (NP the gastrocnemius
	      ,
	      pectoralis
	      major
	      ,
	      transversus abdominis
	      ,
	      biceps brachii
	      ,
	      and
	      diaphragm)))
  (VP showed
      (NP (NP atrophy)
	  (ADVP as
		well
		(PP as
		    (NP (NP (VP varying)
			    degrees
			    (PP of
				(NP injury)))
			(VP ranging
			    (PP (PP from
				    (NP (NP swelling) and (NP vacuolization)))
				(PP to
				    (NP focal necrosis
					(PP of
					    (NP the muscle fibers))))))))))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (NP These changes)
    (VP were
	(ADJP (ADJP   most
		      marked
		      (PP in
			  (NP the gastrocnemius and biceps)))
	      and
	      (ADJP  less
		     evident
		     (PP in
			 (NP the pectoralis
			     ,
			     diaphragm
			     ,
			     and
			     transversus))))))
 .)
(  END_OF_TEXT_UNIT)
( (S (PP In
	 (NP the gastrocnemius and biceps))
     (S
      (NP there)
      (VP were
	  (NP (NP   many
		    (ADJP swollen and homogeneous) necrotic
		    fibers)
	      (ADJP such
		    (PP as
			(NP (NP that)
			    (VP shown
				(PP in
				    (NP Figure 2))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(
 (S (NP  
     Such
     swollen
     fibers)
    (VP (VP were
	    (ADJP  deeply
		   eosinophilic))
	,
	(VP contained
	    (NP a few pyknotic nuclei))
	,
	and
	(VP showed
	    (NP (NP loss
		    (PP of
			(NP cross-striations)))
		,
		(NP obliteration
		    (PP of
			(NP myofibrils)))
		,
		and
		(NP prominent vacuolization)))))
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S (S  
      (NP The necrosis)
      (ADVP often)
      (VP involved
	  (NP  (ADVP only)
	       a portion
	       (PP of
		   (NP the length
		       (PP of
			   (NP a given fiber)))))))
     ,
     and
     (S (ADVP usually)
	(S (NP the
	       (ADJP immediately
		     adjacent) fibers)
	   (VP were
	       (ADJP normal)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP As
       (S  (NP *)  
	   (VP shown
	       (PP in
		   (NP Figure 3)))))
   ,
   (S (NP the protoplasm
	  (PP of
	      (NP other fibers)))
      (VP was
	  (X (ADJP pale
		   ,
		   granular
		   ,
		   or
		   flocculated)
	     and
	     (VP invaded
		 (PP by
		     (NP phagocytes)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Inflammatory cells)
   (VP were
       (ADJP  strikingly
	      absent)))
  .)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP association
	   (PP with
	       (NP these changes
		   (PP in
		       (NP the fibers))))))
   ,
   (S (NP there)
      (VP were
	  (NP (ADJP striking) alterations
	      (PP in
		  (NP the muscle nuclei))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  
 (S (S (NP These)
       (X (X  (AUX were)
	      (VP increased
		  (PP  both
		       (PP in
			   (NP number))
		       and
		       (PP in
			   (NP size)))))
	  ,
	  (VP contained
	      (NP prominent nucleoli))
	  ,
	  and
	  (X  
	   (AUX were)
	   (VP distributed
	     
	       (PP throughout
		   (NP the fiber))))))
    *LRB*
    (NP Figs. 2
	-
	5)
    *RRB*)
 .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP contrast
	   (PP to
	       (NP (NP the nuclear changes)
		   (VP described
		       (ADVP above))))))
   ,
   (S (NP (NP another change
	      (PP in
		  (NP muscle nuclei)))
	  (VP-1 *pseudo-attach*))
      (AUX was)
      (VP seen)
      ,
      (VP-1 (ADVP usually)
	    occurring
	    (PP in
		(NP (NP fibers)
		    (SBAR (SBAR (WHNP that)
				(S  (NP T) 
				    (VP were
					(ADJP  somewhat
					       smaller
					       (PP than
						   (ADJP normal))))))
			  but
			  (SBAR (WHNP that)
				(S  (NP T) 
				    (VP showed
					(NP distinct cross-striations and myofibrillae))))))))))
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( 
 (S (NP The nuclei
	(PP of
	    (NP these fibers)))
    ,
    (PP as
	(S (NP *)  
	   (AUX is)
	   (VP shown
	     
	       (PP in
		   (NP Figures 3
		       and
		       4)))))
    ,
    (X (VP showed
	   (NP remarkable proliferation))
       and
       (X  
	(AUX were)
	(VP  (ADVP closely)
	     approximated)
	,
	(S (NP *)  
	   (VP forming
	       (NP a chainlike structure)
	       (PP at
		   (NP either
		       (NP the center
			   (PP-3 *pseudo-attach*))
		       or
		       (NP the periphery
			   (PP-3 *pseudo-attach*))
		       (PP-3 of
			     (NP the fiber)))))))))
 .) 
(  END_OF_TEXT_UNIT)
( (S
   (NP Individual nuclei)
   (VP were
       (ADJP (ADJP (ADVP usually)
		   oval
		   (PP to
		       (ADJP round)))
	     ,
	     (X though
		(ADJP (ADJP   (ADVP occasionally)
			      elongated)
		      ,
		      and
		      (ADJP (ADJP (ADVP frequently)
				  small)
			    and
			    (ADJP (ADVP somewhat)
				  pyknotic)))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP At
       (NP times))
   ,
   (S (NP clumps
	  (PP of
	      (NP (NP 10
		      (PP to
			  (NP 15)))
		  (ADJP closely-packed)
		  nuclei)))
      (AUX were)
      (ADVP also)
      (VP observed
	  )))
  .)
(  END_OF_TEXT_UNIT)
( (S (S  (ADVP Occasionally)
	 (S (NP there)
	    (VP were
		(NP  (NP small basophilic
			 fibers)
		     (SBAR (WHNP that)
			   (S  (NP T) 
			       (VP (VP were
				       (ADJP devoid
					     (PP of
						 (NP myofibrillae))))
				   and
				   (VP contained
				       (NP many vesicular nuclei
					   (PP with
					       (NP prominent nucleoli)))))))))))
     *LRB*
     (NP Fig. 5)
     *RRB*)
  .) 
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP These)
   (AUX were)
   (VP thought
	     
       (S (NP *)
	  (AUX to)
	  (VP represent
	      (NP  (VP regenerating)
		   fibers)))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S
   (NP Trichrome stains)
   (VP failed
       (S (NP *)
	  (AUX to)
	  (VP show
	      (NP fibrosis)
	      (PP in
		  (NP the (VP involved) muscles))))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
( (S  
   (PP In
       (NP (NP all
	       (PP of
		   (NP the sections)))
	   (VP examined)))
   ,
   (S (NP  the arterioles
	   and
	   small arteries)
      (VP were
	  (ADJP  essentially
		 normal))))
  .)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
(  END_OF_TEXT_UNIT)
